Study guide

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It

Oregon Multistate Pharmacy Jurisprudence Examination MPJE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Oregon Legal Framework

1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy

2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities

2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection

3 Chapter 3: Pharmacy Technicians, Interns & Preceptors

3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision

4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners

4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)

5 Chapter 5: Prescriber Authority & Prescription Requirements

5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority

6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine

7 Chapter 7: Counseling, Language Access & Confidentiality

7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

8 Chapter 8: The Dispensing Process

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse

9 Chapter 9: Nonprescription & Restricted Products

9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others

10 Chapter 10: Product Selection: Generic & Biologic Substitution

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting

11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings

12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies

13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice

13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It

Key Takeaways Explain This Topic AI

Under OAR 855-115-0140, an Oregon pharmacist must review the patient record before dispensing each prescription.

Oregon's eight DUR categories are over- or under-utilization, therapeutic duplication, drug–disease and drug–drug interactions, incorrect dose or formulation, inappropriate duration, drug–allergy interactions, and abuse or misuse.

When an Oregon pharmacist finds a DUR concern, they must mitigate or resolve it and document the steps taken and the outcome.

Oregon technicians and first-year interns may not conduct DUR, and technicians may not override clinical alerts.

An Oregon patient record must include date of birth, preferred language, chronic conditions and allergies.

Last updated: October 2026

Why this matters

Area 3.3 covers prospective drug utilization review (DUR) and, within it, PDMP reporting and access. Oregon's DUR rule is short but strict: the pharmacist must personally review the patient record before each prescription is dispensed, and must document any concern and how it was resolved.

The Oregon DUR rule (OAR 855-115-0140)

Before dispensing each prescription drug or device, a pharmacist must complete a DUR by reviewing the patient record to identify:

DUR category Typical exam example

(a) Over-utilization or under-utilization Early refill of a controlled substance; a gap suggesting non-adherence to an antiepileptic

(b) Therapeutic duplication Two ACE inhibitors, or an ACE inhibitor plus an ARB, from different prescribers

(c) Drug–disease contraindications A nonselective beta-blocker in severe asthma; an NSAID in active peptic ulcer disease

(d) Drug–drug interactions Clarithromycin with simvastatin; sildenafil with nitrates; fluconazole with warfarin

(e) Incorrect drug dosage or formulation Methotrexate "daily" for rheumatoid arthritis; an extended-release product ordered to be crushed

(f) Inappropriate duration of treatment Oral ketorolac beyond the labeled maximum duration

(g) Drug–allergy interactions A cephalosporin in a patient with documented penicillin anaphylaxis (evaluate the history and cross-reactivity)

(h) Drug abuse or misuse Overlapping opioid and benzodiazepine prescriptions from several prescribers

When a concern is found, the pharmacist must take steps to mitigate or resolve it and document the steps taken and the outcome (OAR 855-115-0140(2)).

Who may perform DUR

Pharmacists must personally perform the DUR for each prescription. The Board's self-inspection form says so expressly.

Interns past their first academic year may perform DUR under supervision. First-year interns may only observe (OAR 855-120-0150).

Technicians may not conduct a DUR or drug regimen review, and may not exercise judgment unless a pharmacist verifies it (OAR 855-125-0150). Pharmacy software can flag alerts, but a technician cannot decide whether an alert matters or override it.

The patient record behind the DUR (OAR 855-041-1165)

A DUR is only as good as the patient record. The pharmacist must make a reasonable effort to obtain and keep:

The patient's full name, address, phone, date of birth and gender.

The patient's preferred language for communication and labeling.

Chronic conditions and known allergies, drug reactions and idiosyncrasies .

A list of prescriptions dispensed by this pharmacy (drug, strength, quantity, date, prescriber and Rx number).

Pharmacist comments, and, where relevant, weight, other conditions and OTC or other drugs in use.

Oregon checks the patient-record elements on its self-inspection form for both new and existing patients.

A practical DUR workflow

Validate the prescription (Chapter 5): prescriber authority, required elements and legitimacy.

Review the profile , plus the PDMP when clinically indicated (section 8.2).

Classify each alert or concern using the eight categories, and judge its clinical significance.

Resolve it : contact the prescriber, counsel the patient, adjust within the pharmacist's own authority (for example, a protocol), or decline to dispense.

Document the concern, who was contacted, the decision and the outcome.

Loading diagram...

DUR in special settings

Remote dispensing site pharmacies, kiosks and lockers: the pharmacist performs the DUR before the drug is released, through the telepharmacy system or before stocking (OAR 855-139, 855-141, 855-143).

Central fill and remote processing: the outlet's policies must say how a pharmacist completes and documents a DUR on each prescription, new and refill . Remote processing pharmacies may perform the DUR on behalf of the primary pharmacy (OAR 855-041-3100 to -3130).

Institutional practice: chart orders get pharmacist review under hospital policies. OAR 855-115-0140 applies to dispensing, and the PIC sets institutional procedures.

Tip

A DUR concern doesn't always require calling the prescriber. A chelation interaction between ciprofloxacin and calcium can be resolved by counseling on dose spacing, then documented. A daily methotrexate order for rheumatoid arthritis, or sildenafil with isosorbide mononitrate, needs prescriber clarification before dispensing . Changing the directions yourself is not an option.

Exam scenario

A patient presents a new order for clarithromycin 500 mg twice daily. The profile shows simvastatin 40 mg daily from another prescriber, and a technician says "the system flagged it but it's just a moderate alert." The pharmacist, not the technician, must evaluate the alert. Clarithromycin is a strong CYP3A4 inhibitor and is contraindicated with simvastatin. The pharmacist contacts the prescriber, who switches to azithromycin or advises holding simvastatin during therapy. The pharmacist documents the concern, the call and the resolution under OAR 855-115-0140(2).